Abstract
Blood vessel formation is a fundamental process that occurs during both normal and pathologic periods of tissue growth. In aggressive malignancies such as glioblastoma multiforme (GBM), vascularization is often excessive and facilitates tumor progression. In an attempt to maintain tumors in a state of quiescence, multiple anti-angiogenic agents have been developed. Although several angiogenesis inhibitors have produced enhanced clinical benefits in GBM, many of these pharmacologic agents result in transitory initial response phases followed by evasive tumor resistance. Thus, a significant need exists for the discovery of novel and effective anti-angiogenic therapies. The development of new molecular-targeted therapeutic strategies is often complicated by the complexity of angiogenic signal transduction. Due to the labyrinthine nature of these signaling pathways, increased production of other angiogenic factors may compensate for the inhibition of key vascular targets like vascular endothelial growth factor (VEGF). Such compensatory mechanisms facilitate vascularization and allow tumor growth to proceed even in the presence of anti-angiogenic agents. This review presents the challenges of targeting the intricate vascular network of GBM and discusses the clinical implications for recent advancements in targeted anti-angiogenic drug therapy.
Keywords: Angiogenesis, anti-angiogenic agents, drug resistance, glioblastoma multiforme (GBM), signal transduction, targeted drug therapy, tumor vascularization, vascular network, pro-angiogenic factors, magnetic resonance imaging
Anti-Cancer Agents in Medicinal Chemistry
Title: Angiogenesis in Glioblastoma Multiforme: Navigating the Maze
Volume: 11 Issue: 8
Author(s): Amanda G. Linkous and Eugenia M. Yazlovitskaya
Affiliation:
Keywords: Angiogenesis, anti-angiogenic agents, drug resistance, glioblastoma multiforme (GBM), signal transduction, targeted drug therapy, tumor vascularization, vascular network, pro-angiogenic factors, magnetic resonance imaging
Abstract: Blood vessel formation is a fundamental process that occurs during both normal and pathologic periods of tissue growth. In aggressive malignancies such as glioblastoma multiforme (GBM), vascularization is often excessive and facilitates tumor progression. In an attempt to maintain tumors in a state of quiescence, multiple anti-angiogenic agents have been developed. Although several angiogenesis inhibitors have produced enhanced clinical benefits in GBM, many of these pharmacologic agents result in transitory initial response phases followed by evasive tumor resistance. Thus, a significant need exists for the discovery of novel and effective anti-angiogenic therapies. The development of new molecular-targeted therapeutic strategies is often complicated by the complexity of angiogenic signal transduction. Due to the labyrinthine nature of these signaling pathways, increased production of other angiogenic factors may compensate for the inhibition of key vascular targets like vascular endothelial growth factor (VEGF). Such compensatory mechanisms facilitate vascularization and allow tumor growth to proceed even in the presence of anti-angiogenic agents. This review presents the challenges of targeting the intricate vascular network of GBM and discusses the clinical implications for recent advancements in targeted anti-angiogenic drug therapy.
Export Options
About this article
Cite this article as:
G. Linkous Amanda and M. Yazlovitskaya Eugenia, Angiogenesis in Glioblastoma Multiforme: Navigating the Maze, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (8) . https://dx.doi.org/10.2174/187152011797378643
DOI https://dx.doi.org/10.2174/187152011797378643 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Current Cancer Drug Targets Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Tankyrase Inhibitors as Therapeutic Targets for Cancer
Current Topics in Medicinal Chemistry subject Index To Volume 2
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents State-of-the-Art Magnetic Resonance Spectroscopy in Oncologic Imaging
Current Molecular Imaging (Discontinued) Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Non-Camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Double Edge Sword Behavior of Carbendazim: A Potent Fungicide With Anticancer Therapeutic Properties
Anti-Cancer Agents in Medicinal Chemistry New Insights into Pre-, Intra- and Post-Operative Brain Mapping in Low- Grade Glioma Surgery: Towards a Longitudinal Study of Cerebral Plasticity
Current Medical Imaging New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design